Safety Evaluation of Contezolid (MRX-I) Versus Linezolid in Sprague-Dawley Rats
Abstract Background & Objectives Contezolid (MRX-I) is a novel ortho-fluorophenyl dihydropyridone developed by MicuRx Pharmaceuticals, Inc. It has been approved for the treatment of drug-resistant Gram-positive bacterial infections with relatively lower toxicity than other oxazolidinones such as lin...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Adis, Springer Healthcare
2025-05-01
|
| Sraith: | Drugs in R&D |
| Rochtain ar líne: | https://doi.org/10.1007/s40268-025-00504-x |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|